Circulating tumor cell surface protein or nucleic acid (CTC surface protein/nucleic acid)

Circulating tumor cells are rare cancer cells found in the blood of patients with solid tumors, shed from the primary or metastatic lesion and responsible for metastatic spread[1][3][6]. They are distinguished by their expression of specific surface proteins (such as EpCAM and cytokeratins) and tumor-derived nucleic acids, which are used for their detection, isolation, and molecular characterization[4][5]. These molecules serve as important biomarkers for prognosis, patient stratification, and monitoring response to therapy. The heterogeneity of CTCs with respect to their surface proteins and nucleic acids reflects various tumor origins, treatment-induced changes, and acquisition of stemness (like EMT transition), which makes them both a valuable target for research and a challenge for consistent clinical application[2][3][4]. While no drugs directly target this molecular class, technologies for CTC detection rely on these markers, and their study provides crucial insight into metastasis biology, minimal residual disease, and mechanisms of therapeutic resistance[5][6].

Other names

CTC surface markerCirculating tumor cell biomarkerCTC nucleic acidCTC molecular marker

Null (not applicable; detection and isolation technologies use antibody binding, microfluidics, or electrochemical recognition, but no drugs inhibit “CTC surface protein/nucleic acids” generically)